Page 6 - Daniel Mackey News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Infant Bacterial Therapeutics AB: Infant Bacterial Therapeutics publishes Annual Report for 2020 The report is available on IBT's website ibtherapeutics.comunder the section "Investors & Media - Financial Reports" and is available in printed form for those that have requested. A copy can be requested by contacting IBT's office via info@ibtherapeutics.com. About Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a product in clinical stage with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare ...

Infant Bacterial Therapeutics today announces that new patent protection is granted in Japan Infant Bacterial Therapeutics AB today announces that the Japan Patent Office has issued a decision to grant a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of NEC and improvement of feeding tolerance in preterm infants. The invention covers a novel way to activate the freeze-dried bacteria and corresponding patent applicat...

Message from the CEO IBT is currently developing its lead drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), and to improve so-called "feeding tolerance" in premature infants. IBP-9414 contains Lactobacillus reuteri as an active ingredient, which is a human bacterial strain found naturally in breast milk.  This message from the CEO is written during the continuing COVID-19 pandemic which now has been ongoing for one year. The pandemic appeared to be under control during the fall, however the outbreak of COVID worsened during November and December in many parts of the world....

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 - December 31, 2020 Message from the CEO IBT is currently developing its lead drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), and to improve so-called "feeding tolerance" in premature infants. IBP-9414 contains Lactobacillus reuteri as an active ingredient, which is a human bacterial strain found naturally in breast milk. This message from the CEO is written during the continuing COVID-19 pandemic which now has been ongoing for one year. The pandemic appeared to be under control during the fa...